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Assessment, Development and Evaluation) Methods: We evaluated the primary 
endpoint of a random sample from efficacy and effectiveness studies included in 
a systematic review on the treatment of rheumatoid arthritis with anti-TNFs. The 
quality assessment was conducted in accordance with the recommendations of the 
GRADE Working Group available at: www.gradeworkinggroup.org/toolbox/index.
htm. It assigns at first high quality for trials and low quality for observational stud-
ies. Results: The assessment of 8 efficacy and 8 effectiveness studies showed 
respectively that the quality of evidence were high in 5 and 0; moderate in 3 and 
2; low in 0 and 2; and very low in 0 and 4. The risk of bias was present in 3 and 5; 
imprecision results in 0 and 5; elevated magnitude of effect in 6 and 4; controlled 
confounding bias in 0 and 3; presence of dose-response gradient in 0 and 1. Indirect 
evidence and inconsistencies were not found in any of the studies. ConClusions: 
The quality of evidence of 3 trials and 4 observational studies were downgraded, while 
2 observational studies had the quality assessment increased.
PRM216
What Value Can OPeRatiOnal Feasibility studies bRing tO POst 
MaRketing ObseRVatiOnal studies (PMOs)? exaMPle OF Feasibility 
study PeRFORMed in easteRn euROPe tO assess hePatitis C ViRal 
disease/Patient ManageMent in Real WORld setting
El Kebir S., Bayle D., Gauchoux R.
Mapi, Real World Evidence, Lyon, France
objeCtives: Operational feasibility studies provide a good opportunity to assess 
practicality of large full-scale studies. They are an almost essential pre-requisite and 
should be well designed with clear objectives. Conducting a pilot study can enhance 
the likelihood of success of PMOS and potentially help to avoid serious design flaws. 
The objective of this research is to assess the value of feasibility studies prior to 
PMOS implementation and highlight the importance of local physicians’ feed-
back. Methods: A feasibility study in 6 Eastern European countries was conducted 
via collection of physician surveys to assess local standard of care. The feasibility 
questionnaire was developed to assess operational aspects, such as availability of 
patient population, site experience and time and willingness to participate. The 37 
physicians who received the questionnaire were selected through PubMed; they 
were all experts who have published regarding HCV infection and were provided 
with the protocol synopsis Results: Out of the 37 selected physicians, 18 gastro-
enterologists, hepatologists, and infectious disease specialists in Bulgaria, Croatia, 
The Czech Republic, Hungary, Poland and Romania completed the questionnaire. 
The participating Physicians were working exclusively in public institutions. The 
average number of HCV patients seen by year is 140 and out of them 78 are treated 
by Interferon. They specified that they can enrol 2 eligible patients per month on 
average. They see their patients frequently during treatment initiation (bi-weekly 
or monthly). However, the follow-up varies from one country to another (quarterly 
or semi-annually). Physicians indicated that patient records and data regarding 
blood tests and procedures are accessible for 100% of the cases. Over 60% of the 
sites were familiar with Patient Reported Outcomes. Overall, 12 physicians were 
interested in participating in the Study. ConClusions: The result of this survey 
helped us documenting routine medical practice and confirming the study design 
and methodology to be implemented.
PRM217
use OF suRROgate OutCOMes in health teChnOlOgy assessMents 
(htas)
Jaksa A., Ho Y.S., Daniel K.
Context Matters, Inc., New York, NY, USA
objeCtives: This study analyzes how frequently surrogate outcomes are used 
in HTAs and if the validity of these outcomes are discussed and reported within 
the HTAs. A surrogate outcome is defined by the National Institutes of Health as 
a biomarker intended to substitute for a clinical endpoint. A surrogate outcome 
is used when a clinical endpoint of interest is not ideal or does not occur often 
enough to perform meaningful statistical analysis. It is appropriate to use a sur-
rogate outcome only when there is a strong correlation with the clinical endpoint. 
Before using surrogate outcomes researchers should confirm that the surrogate 
outcome is biologically plausible, has a magnitude of association with the clini-
cal endpoint, and reflects changes in the relevant clinical endpoint. Methods: 
Context Matters (CM) analyzed 1,056 HTAs spanning 38 disease conditions. Each 
HTA had a primary outcome that could be classified as either a surrogate outcome 
or a clinical endpoint. Data was analyzed for eight HTA agencies: AHRQ, DERP, 
SMC, HAS, PBAC, NICE, CADTH, and HIS Scotland. For those HTAs using a sur-
rogate outcome as the primary outcome, CM then determined if the HTA agency 
reported the use of the surrogate and/or discussed the surrogate outcome’s valid-
ity. Results: Ninety-one percent of HTAs used a surrogate outcome (966 HTAs), 
but only 11% (109 HTAs) identified it as a surrogate outcome and/or discussed 
its validity. The agencies that discussed the use of the surrogate outcome most 
often were AHRQ, DERP, and HIS Scotland at 48.1%, 28.6%, and 29.0% of the time, 
respectively. ConClusions: Surrogate endpoints are prevalent in HTAs, but the 
agencies rarely discuss the validity of these endpoints. All agencies failed to dis-
cuss the use of the surrogate endpoint in over 50% of their reviews. HTA agencies 
are not following best practice use of surrogate outcomes.
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in EMBASE and MEDLINE, search terms ‚hemophilia B‘ and ‚FIX‘. Inclusion crite-
ria: journal articles (JA), conference abstracts (CA), English language, published 
between January 2009 and March 2013, studies only. Screening of titles, abstracts 
and full texts was performed subsequently. Registered trials (RT) concerning HB 
or FIX were identified in ClinicalTrials.gov. Analysis comprised age group, spon-
sor, research topic, recruitment status, and study design. Results: Screening of 
1,639 hits yielded 31 JA describing 35 studies, and 62 CA. FIX was the topic of 21 
studies (60.0%) and 29 CA (46.8%). A total of 7 studies focused on various aspects 
of HB, 6 on haemophilia studies with separate data on HB. Gene therapy was the 
main focus of 2 JA and 11 CA (17.7%). Screening of 173 hits from ClinicalTrials.gov 
yielded 47 RT, 42 unpublished. Overall 32 unpublished RT (76.2%) concerned FIX, and 
4 (9.5%) gene therapy. Randomized study design was described in one study (2.9%) 
and 4 RT (9.5%), and 3 studies (8.6%) and 7 RT (16.7%) were prospective observa-
tional comparative. ConClusions: Randomized study design or comparator arms 
were uncommon, and payers’ requirements for evidence were not met. Therefore, 
randomization, comparison to standard of care and documentation of outcome 
should be discussed. Development of refined statistical methods and exploitation 
of complementary data like real-life data may help to fill actual evidence gaps in 
rare diseases.
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the ROle OF dsM in the eMa and Fda authORizatiOn PROCess FOR 
PsyChiatRiC dRugs
Meyers O.I.
Truven Health Analytics, Cleveland, OH, USA
objeCtives: In May 2013, the American Psychiatric Association released the fifth 
edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5). This 
is significant for clinicians, researchers, and developers of psychopharmacologic 
drugs. The previous version of the DSM, the DSM-IV-TR, was published in 2000 and 
the last time the diagnostic criteria were revised was in 1994, when the DSM-IV 
was published. The objective of this review was to determine how much of a role 
DSM has played in the drug approval process in Europe and the US. Methods: For 
drugs authorized since 2000, summaries of product characteristics (SPCs; EMA) and 
approved labels (FDA) were reviewed to determine how frequently the DSM is men-
tioned in the “clinical particulars” or “indications” sections and how frequently DSM 
criteria are mentioned in the clinical trials sections of the SPCs or labels. The review 
focused on schizophrenia and psychotic disorders, mood disorders, and for the 
FDA, attention-deficit/hyperactivity disorder as well. Results: For EMA-authorized 
products, 8 EPARs met the criteria with 10 indications in total. The DSM was never 
mentioned in the indications or posology sections, but in 7 (70%) of the descriptions 
of pharmacodynamic properties (section 5.1), DSM criteria were cited as the study 
inclusion criteria. For FDA-approved products, 17 labels with 22 indications met the 
review criteria. The DSM was mentioned in 10 of the indications sections (45%) and 
DSM criteria were cited as inclusion criteria in 20 instances (91%). ConClusions: 
Regulators in Europe and the US rely heavily on DSM diagnostic criteria, in the 
sense that these often serve as inclusion criteria for pivotal clinical trials. Given 
significant changes to the criteria in many diagnostic categories, regulators and 
sponsors need to familiarize themselves with the document and evaluate their use 
of DSM criteria going forward.
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POdCasts as a leaRning tOOl in a ReseaRCh MethOds COuRse FOR 
PhaRMaCy students
Nguyen T.L., Lovett A.W., Lundquist L.M., Bonner C.L.
Mercer University College of Pharmacy and Health Sciences, Atlanta, GA, USA
objeCtives: Podcasts (recorded lectures) can be beneficial for all students, particu-
larly English as a second language students who face language barriers when learn-
ing in another language. There is limited study on pharmacy student perceptions 
and podcasts, none from an international perspective. The primary objective was 
to describe pharmacy students’ perceptions on the usefulness of podcasting and a 
secondary objective was to compare perceptions between native versus non-native 
English speakers in a pharmacy research course. Methods: All first year phar-
macy students (n= 157) attending a Research Methods course in 2012 were invited 
to participate in a survey, which utilized a 4-point Likert Scale (1= strongly disagree, 
2= disagree, 3= agree, and 4= strongly agree). Podcasts covered all course topics such 
as Applied Statistics, Odds Ratio and Relative Risk, Case Reports, Observational 
Studies, Randomized Controlled Trials, and Economic Evaluations. Descriptive sta-
tistics and t-tests were utilized to analyze the data in SPSS. The study was approved 
by the Institutional Review Board. Results: A total of 73% of the class completed 
the survey (40.2% Caucasian, 32% Asian and 25% African American). A total of 24.1% 
identified themselves as non-native English speakers, 94.6% lived in the US for 
greater or equal to 5 years and 66.1% communicated in English at home. The major-
ity of students agreed/strongly agreed that podcasts helped them to prepare for 
exams (92.9%), podcasts were a useful learning tool (91.2%), promoted understand-
ing of course material (89.3%), helped with missed concepts (96.4%), and facilitated 
note-taking at their own pace (92.2%) with mean scores 3.34, 3.27, 3.27, 3.48 and 3.48, 
respectively. Results of the t-test revealed that there is no statistically significant 
difference between native versus non-native English speaking students in their 
perceptions of podcast usefulness (p> .05). ConClusions: Podcasts are beneficial to 
a majority of students, despite their language background. Podcasts have the poten-
tial to be a valuable learning tool for students taking a research methods course.
PRM215
gRade FOR Quality assessMent OF eFFiCaCy and eFFeCtiVeness 
studies On anti-tnFs tReatMent OF RheuMatOid aRthRitis
Taino B, Nobre M.R.C
INCOR - HCFMUSP, Sao Paulo, Brazil
objeCtives: Assess the quality of evidence on experimental and observational clini-
cal research through the same approach named GRADE (Grading of Recommendations 
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by critical evaluation against traditional CEA (Cost Effective Analysis) via a scien-
tific process. Patient and Public Involvement (PPI) in HTA is associated with a low 
evidence base potentially limiting its value. Research presented at ISPOR 2012 by 
the same authors concluded a need to improve and standardize PAG input integra-
tion in HTA decision making. To investigate the way different forms of knowledge / 
experience are used by PAGs in NICE HTA for guideline development and new tech-
nology review. We will look at: 1) Influence of PAG structure, resource capability, 
internal process and the impact of PAG advisory board physician representatives 
on scientific validation of patient input in HTA participation, and 2) Part I results 
will inform further research into selection and ranking criteria of social derived 
data compared with CEA. An iterative PPI best practice approach will be followed. 
Selection criteria: Five UK PAG groups (Neurological, Autoimmune, Rare disease, 
Cardiovascular and Oncology) will be invited to participate. The NICE PPI Unit will 
nominate groups when needed. Inclusion criteria: 1) willingness to participate, 
2) prior involvement in guideline / new technology assessments; and 3) pres-
ence of medical advisory board. Research elements: Application of GRIPP criteria 
(Guidance Reporting Involvement Patient Public) to ensure a strong evidence base 
will guide development of an on-line survey and subsequent focus groups and 
interviews. The survey, designed for SAP review, will study: size of PAG, internal 
process for HTA involvement, previous HTA involvement, data submitted, PAG 
knowledge gaps and involvement of medical advisory board. Follow up by focus 
groups and interviews with PAG and advisory board members to identify insights/ 
themes.
PRM222
Juggling JuRisdiCtiOns: MethOds FOR COnduCting MOdulaR 
systeMatiC ReVieWs?
Thompson J., Hawkins N.
Oxford Outcomes Ltd., Oxford, UK
A crucial component of a systematic review is a clear description of the disposi-
tion of studies throughout the various steps of the review process (de-duplication, 
abstract review, full paper review and final inclusion). This is commonly achieved 
using a PRISMA diagram that shows the number of inclusions and exclusions at 
each stage of the review. This may be supplemented with details of the reasons for 
exclusion. To create the PRISMA diagram it is necessary to keep an on-going count of 
exclusions and inclusions throughout the review process. However, this can pose a 
challenge where the scope of a systematic review changes from the original specifi-
cation. This may happen where the set of licensed treatments or HTA requirements 
vary between jurisdictions or over time. In these cases, it may be time consuming to 
recreate the on-going counts of exclusions that correspond to the modified scope. 
We present a methodology for conducting a modular systematic review in which 
PRISMA diagrams and other descriptions of study disposition can be generated 
corresponding to any subsequent changes of scope. This is achieved by splitting 
the review into a set of ‘component-reviews’ defined by mutually exclusive treat-
ment search terms that comprise the full set of possible intersections between the 
individual treatments. Throughout the systematic review process separate counts of 
abstracts, papers and studies are maintained for each of these component-reviews. 
The results from the component-reviews can then be combined to reflect any final 
review scope (based on individual treatments). We will illustrate the methodology 
with an example review of the comparative efficacy of licenced thiazolidinedione’s 
(TZDs) versus placebo in patients with type 2 diabetes mellitus (T2DM) where there 
are two TZDs licensed in the USA (pioglitazone and rosiglitazone) but only one in 
Europe (pioglitazone).
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sOCial netWORk analysis OF authORshiP netWORks and the 
identiFiCatiOn OF exPeRt adVisORs
Stoddart S.D.R.1, Siddiqui M.K.2
1HERON Evidence Development Ltd., London, UK, 2Heron Health Private Ltd., Chandigarh, India
objeCtives: Systematic reviews are often supplemented with the use of external 
experts to provide guidance on the nuances of the area. This can help add context 
if a review is used to support trial design or health economic model development. 
The ideal expert would have a deep understanding of the area and be well con-
nected to those individuals conducting trials. The aim of the current research 
was to assess whether social network analysis of coauthor networks could be 
used to rapidly and objectively identify individuals with the qualities desired in 
an external expert. Methods: Publication lists from a recent systematic review 
of rheumatoid arthritis were used to produce a list of links between authors and 
publications. This was then imported into the Gephi program for social network 
analysis. Within Gephi, matrix multiplication was used to transform this net-
work into a coauthorship network. Eigenvector centrality was then used to infer 
the amount of access individual authors have to the research community as a 
whole. The use of eigenvector centrality as a measure of influence within the 
author network was then validated by correlating the centrality scores of a random 
sample of authors against independent ratings of desirability of those individu-
als’ expertise. Results: The coauthor network for rheumatoid arthritis, while 
not completely connected, showed a high degree of connectivity (mean degree: 
26, network diameter: 5). Eigenvector centrality allowed the identification of key 
experts, with the highest scoring experts each providing direct access to approxi-
mately half of the whole network. Eigenvector centrality measures were a reli-
able predictor of mean desirability scores from ten raters (F(1,9)= 20.35, p= 0.0015, 
R-squared= 0.69). ConClusions: Social network analysis of coauthor networks 
provides an efficient and robust method for the identification of expertise, and 
can be used as part of the systematic review process.
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objeCtives: Use of economic evaluation of health care technologies is intensively 
discussed in the government in Japan. In order to make evaluation results compa-
rable, standardized method of evaluation is required. We proposed an economic 
evaluation guideline in Japan. Methods: We organized a research team for devel-
oping guideline. After reviewing guidelines in HTA agencies in the world and cur-
rent debate on issues, we investigated HTA reports and methodology of economic 
evaluation studies in several drugs, devices and procedures. Based on the review of 
these information, the research group discussed and proposed economic evalua-
tion guideline suitable for Japan. Results: Proposed guideline consist of 13 items: 
1) Objective; 2) Perspective of analysis; 3) Comparators; 4) Method of analysis; 
5) Time horizon; 6)Choice of outcomes; 7) Source of clinical data; 8) Costs; 9) 
Productivity loss; 10) Discounting; 11) Modeling; 12) Uncertainty; and 13) Budget 
impact analysis. Guideline sentences are classified into 3 levels, principal, recom-
mended, and optional. ConClusion: This guideline is a proposal by a research 
team. However, it will be needed in the near future for using economic evalua-
tion of health care technologies. Proposed guideline should be tested by adopting 
individual studies.
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dealing With zeRO Cells in sPaRse netWORks in bayesian netWORk 
Meta-analysis
Ivanescu C.1, Skaltsa K.2, Heemstra L.1, Van Engen A.1
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objeCtives: Bayesian Network Meta-Analysis (NMA) models for binary data 
are well established and special precautions do not usually need to be taken in 
the case of zero cell counts. Furthermore, trials with zero cells in both arms are 
usually excluded from the analysis. However, in sparse networks with only one 
trial per comparison and zero cells in unique link studies, their inclusion may 
be mandatory. Zero frequencies may result in numerical instability and/or large 
variances. The objective of this study was to investigate the effect of different 
methods dealing with zero cells in sparse networks in Bayesian NMA. Methods: 
A review was conducted to identify methods dealing with zero cells for binary 
outcomes in sparse networks in a Bayesian setting. The identified methods were 
applied to a sparse network with six treatments and one study per comparison. 
The outcome was grade 3+ Adverse Events and measured by Odds Ratio. A fixed 
effects model was fitted with binomial likelihood. The performance of the meth-
ods was assessed by the residual deviance and the Credible Intervals’ (CrI) width 
was compared. Results: We identified three methods: apply a continuity cor-
rection (a constant factor of 0.5 or the reciprocal of the opposite treatment size), 
use of informative priors on treatment effects and placing a distribution on the 
baseline model. We applied all methods and combinations of them. The model 
fit was adequate for all methods (residual deviance [10;12.3] for 12 datapoints). 
The use of different informative priors improved the variability estimates. CrI 
widths were reduced up to 15 times with respect to the original model with vague 
priors. ConClusions: Although the debate on the inclusion of studies with zero 
events in NMA is still open, our research shows that methods are available to 
address this issue. However, no clear recommendations can be provided.
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Quality assessMent OF ObseRVatiOnal studies FOR systeMatiC 
ReVieWs
Kiss N., Tongbram V., Fortier K.J.
Oxford Outcomes, Morristown, NJ, USA
Observational studies are frequently included in systematic reviews, especially in 
those disease areas where RCTs are limited. While there are very specific tools for 
and guidance on assessing the quality of RCTs, the assessment of observational 
studies is less standardized. OBJECTIVE: To understand and assess the different tools 
used to review the quality of observational studies and to make recommendations 
based on our evaluation. Methods: First, a systematic review of literature from 
2005-present was conducted in Embase and Medline to determine the frequency 
of use of quality assessment for observational studies and the type of tools used to 
conduct the assessment. Second, we reviewed documentation from NHS guidance 
on quality assessment of non-randomized studies. Finally, we reviewed two years of 
approved HTA submissions to see what methods of assessment have been used for 
submissions. Results: A total of 1429 articles were screened. Compared to a similar 
study on older literature, our review found an increase in the use of quality assess-
ment for observational studies. However, we found that many studies continue to 
devise their own tool or adapt existing tools rather than use a tool in its entirety. 
Downs and Black, MOOSE, and STROBE were the most referenced tools, although 
STROBE was not originally intended for such use. Guidelines centered on “non-ran-
domized” studies were mixed and were not always found to be applicable to obser-
vational studies, but instead mostly to single-armed clinical trials. ConClusions: 
There is still a need for guidance and standardization for observational studies 
assessment for use in systematic literature reviews. Although quality assessment 
of observational studies is still not standardized, there are a few methods becom-
ing more frequent in the literature but are difficult to compare across systematic 
literature reviews because they have often been adapted by each author.
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an aPPROaCh FOR QuantiFiCatiOn OF Patient adVOCaCy gROuP inPut in 
the hta PROCess
Hicks N.1, Toumi M.2
1Commutateur, Paris, France, 2University Claude Bernard Lyon 1, Lyon, France
Patient input in HTA pathways by the appropriate disease Patient Advocacy Group 
(PAG) uses principally humanistic and social studies as an evidence base followed 
